ATE183652T1 - Synthetische peptide für die behandlung von myasthenia gravis - Google Patents

Synthetische peptide für die behandlung von myasthenia gravis

Info

Publication number
ATE183652T1
ATE183652T1 AT93916644T AT93916644T ATE183652T1 AT E183652 T1 ATE183652 T1 AT E183652T1 AT 93916644 T AT93916644 T AT 93916644T AT 93916644 T AT93916644 T AT 93916644T AT E183652 T1 ATE183652 T1 AT E183652T1
Authority
AT
Austria
Prior art keywords
treatment
myasthenia gravis
peptides
amino acid
synthetic peptides
Prior art date
Application number
AT93916644T
Other languages
English (en)
Inventor
Michael Sela
Edna Mozes
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of ATE183652T1 publication Critical patent/ATE183652T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT93916644T 1992-06-18 1993-06-18 Synthetische peptide für die behandlung von myasthenia gravis ATE183652T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90039392A 1992-06-18 1992-06-18

Publications (1)

Publication Number Publication Date
ATE183652T1 true ATE183652T1 (de) 1999-09-15

Family

ID=25412446

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93916644T ATE183652T1 (de) 1992-06-18 1993-06-18 Synthetische peptide für die behandlung von myasthenia gravis

Country Status (11)

Country Link
EP (1) EP0646016B1 (de)
JP (1) JP3996635B2 (de)
AT (1) ATE183652T1 (de)
AU (1) AU678372B2 (de)
CA (1) CA2138258C (de)
DE (1) DE69326145T2 (de)
DK (1) DK0646016T3 (de)
ES (1) ES2139667T3 (de)
GR (1) GR3031371T3 (de)
IL (3) IL122445A0 (de)
WO (1) WO1994000148A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6066621A (en) * 1989-12-10 2000-05-23 Yeda Research And Development Co. Ltd. Synthetic peptides for the treatment of myasthenia gravis
US5843462A (en) * 1995-11-30 1998-12-01 Regents Of The University Of Minnesota Diphtheria toxin epitopes
EP1037663A2 (de) 1997-12-16 2000-09-27 Regents Of The University Of Minnesota Verfahren zur behandlung unerwünschter immunantworten
WO2000005249A2 (en) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Synthetic peptides and methods of use for autoimmune disease therapies
WO2022260579A2 (en) 2021-06-07 2022-12-15 Toleranzia Ab Fusion protein in myasthenia gravis
TW202444434A (zh) * 2023-03-24 2024-11-16 美商庫爾製藥發展公司股份有限公司 用於重症肌無力治療之免疫修飾奈米粒子之處理

Also Published As

Publication number Publication date
EP0646016A4 (de) 1995-07-12
ES2139667T3 (es) 2000-02-16
CA2138258A1 (en) 1994-01-06
IL122445A0 (en) 1998-06-15
JPH07508521A (ja) 1995-09-21
DE69326145T2 (de) 2000-04-27
AU4642993A (en) 1994-01-24
IL106065A0 (en) 1993-10-20
EP0646016B1 (de) 1999-08-25
IL106065A (en) 1999-10-28
IL122445A (en) 2000-08-31
JP3996635B2 (ja) 2007-10-24
GR3031371T3 (en) 2000-01-31
CA2138258C (en) 2003-08-19
DE69326145D1 (de) 1999-09-30
WO1994000148A1 (en) 1994-01-06
AU678372B2 (en) 1997-05-29
DK0646016T3 (da) 2000-03-20
EP0646016A1 (de) 1995-04-05

Similar Documents

Publication Publication Date Title
ATE108662T1 (de) Antimikrobielle peptide, zusammensetzungen, die diese enthalten, und verwendungen daraus.
ES2158360T3 (es) Mimeticos de rotacion en sentido inverso y metodos relacionados con ellos.
DE69532605D1 (de) Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
DE69006306D1 (de) Synthetische peptide des konjugates von ubiquitin und histon h2a.
IE891542L (en) Peptides having t cell helper activity
DE68925226D1 (de) Monoklonale Antikörper
NO873495D0 (no) Monoklonale antistoffer og peptider egnet for behandling og diagnose av hiv-infeksjoner.
CA2208274A1 (en) Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes
HUP9901688A2 (hu) A diabétesz kezelésére szolgáló, humán hősokk protein 60-ból származó új peptidek, készítmények, eljárások és kitek
DK0687180T3 (da) Fremgangsmåde til påvisning og behandling af individer, som har unormale celler, som udtrykker HLC-A2/tyrosinasepeptid-anti
DE69326145D1 (de) Synthetische peptide für die behandlung von myasthenia gravis
NO971517L (no) Peptider og farmasöytiske sammensetninger omfattende dem
DE69607962D1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
DE3887053D1 (de) Stlv-iii-verwandte polypeptide, diagnosesysteme und testmethoden.
WO1992021697A3 (en) Diagnostic peptides derived from m.tuberculosis antigens
DK0764273T3 (da) Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ATE216707T1 (de) Peptide und ihre verwendung in der therapie von krankheiten des zöliakie-formenkreises
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
NO900255L (no) Peptider med t-cellehjelperaktivitet.
RU93005016A (ru) Иммунорегуляторные и нейрорегуляторные пентапептиды, фармацевтические композиции на их основе, способ получения пентапептидов, способ лечения
FR2621488B1 (fr) Produit comprenant a titre de principes actifs a) un peptide ayant une activite du type de celle de l'interferon gamma humain, b) l'hyfroxyuree
ATE100820T1 (de) Synthetische peptide des konjugates von ubiquitin und histon h2a.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee